Private company
CTI BioPharma
Logo: Bisvictor, CC BY-SA 4.0, via Wikimedia Commons3
Pharmaceutical company based in Seattle, USA.1
Last updated Oct 16, 2026.
Overview
2014Founded1
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2022
Where the money goes
Where each dollar of revenue went, fiscal 2022
- Cost of revenue3¢$3.5M
- Selling, general and admin84¢$84.8M
- Interest13¢$13.1M
Out of $53.9M in revenue.5 The company lost money this year.
Financial statements
No quarterly figures reported.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenue | $57.4M6 | $25.1M7 | $26.3M8 | $3.3M9 | $09 | $05 | $53.9M5 |
| Cost of revenue | $1.4M6 | $364.0K7 | $879.0K7 | $05 | $3.5M5 | ||
| Selling, general and admin | $45.3M6 | $31.4M7 | $22.1M8 | $19.2M9 | $17.6M10 | $56.2M5 | $84.8M5 |
| Operating income | -$49.2M6 | -$39.5M7 | -$32.9M8 | -$40.7M9 | -$47.8M10 | -$95.3M5 | -$79.8M5 |
| Interest | $2.6M6 | $1.9M7 | $1.2M8 | $1.0M9 | $828.0K10 | $2.4M5 | $13.1M5 |
| Net income | -$52.0M6 | -$40.7M7 | -$29.3M8 | -$40.0M9 | -$52.5M10 | -$97.9M5 | -$93.0M5 |
| Earnings per share | -$0.7410 | -$1.095 | -$0.815 | ||||
| Earnings per share (diluted) | -$0.7410 | -$1.095 | -$0.815 |
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Cash | $44.0M6 | $27.2M7 | $36.4M8 | $31.1M9 | $40.4M10 | $65.4M5 | $30.4M5 |
| Current assets | $55.8M6 | $46.9M7 | $82.5M8 | $35.6M9 | $54.3M10 | $68.4M5 | $99.4M5 |
| Total assets | $63.8M6 | $54.9M7 | $89.8M8 | $46.3M9 | $58.2M10 | $72.4M5 | $125.9M5 |
| Current liabilities | $40.6M6 | $19.3M7 | $23.1M8 | $18.5M9 | $17.0M10 | $66.7M5 | $81.1M5 |
| Long-term debt | $11.3M6 | $13.6M7 | $9.3M8 | $4.5M9 | $09 | $47.4M10 | $47.9M5 |
| Total liabilities | $56.1M6 | $38.8M7 | $36.9M8 | $28.4M9 | $18.2M10 | $68.7M5 | $143.5M5 |
| Shareholders’ equity | $13.3M6 | $21.8M7 | $58.7M8 | $23.7M9 | $40.0M9 | $3.8M5 | -$17.6M5 |
| Shares outstanding | 28.2M shares6 | 43.0M shares7 | 58.0M shares8 | 58.0M shares9 | 75.9M shares10 | 99.8M shares5 | 130.7M shares5 |
Former names
- CELL THERAPEUTICS INCJun 28, 1996 to May 29, 20144
Timeline
- 2014Founded Founded1
Recent filings
- Jun 28, 20234 OWNERSHIP DOCUMENT
- Jun 26, 20238-K
- Jun 26, 20234 FORM 4 SUBMISSION
- Jun 26, 20234 FORM 4 SUBMISSION
- Jun 26, 20234 FORM 4 SUBMISSION
- Jun 26, 20234 FORM 4 SUBMISSION
- Jun 26, 20234 FORM 4 SUBMISSION
- Jun 26, 20234 FORM 4 SUBMISSION
- Jun 26, 20234 FORM 4 SUBMISSION
- Jun 26, 20234 FORM 4 SUBMISSION
- Jun 26, 20234 FORM 4 SUBMISSION
- May 30, 20238-K
- May 15, 202310-Q
- May 10, 20238-K
- Apr 28, 2023DEF 14A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.ctibiopharma.com1
- WikidataQ28669445
- SEC EDGARCIK 891293
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataCTI BioPharma on Wikidata
- 2SEC EDGARCTI BioPharma filings on SEC EDGAR
- 3Wikimedia CommonsCTI BioPharma logo by Bisvictor, CC BY-SA 4.0
- 4SEC EDGARCTI BioPharma filings on SEC EDGAR
- 5SEC EDGARCTI BioPharma 10-K for fiscal 2022
- 6SEC EDGARCTI BioPharma 10-K for fiscal 2016
- 7SEC EDGARCTI BioPharma 10-K for fiscal 2017
- 8SEC EDGARCTI BioPharma 10-K for fiscal 2018
- 9SEC EDGARCTI BioPharma 10-K for fiscal 2019
- 10SEC EDGARCTI BioPharma 10-K for fiscal 2020
- 11SEC EDGARCTI BioPharma 10-Q for fiscal 2023